Remus Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #38 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Remus Pharmaceuticals Ltd Q1 FY26 key numbers
- Revenue
- Standalone Revenue from Operations for FY25 is INR 792 Mn, up from INR 639 Mn in FY24, around a 24% YoY growth.
As stated in Remus Pharmaceuticals Ltd's Q1 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Remus Pharmaceuticals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY). EBITDA (Consolidated) for FY25: INR 457 Mn; FY24: INR 290 Mn; EBITDA margin FY25: 7.37%, FY24: 13.62% (margin decline YoY) - PAT (Consolidated) for FY25: INR 384 Mn; FY24: INR 243 Mn; PAT margin FY25: 6.19%, FY24: 11.41% (margin decline YoY) - Revenue From Operations (Consolidated) FY25: INR 6,204 Mn; FY24: INR 2,129 Mn (substantial YoY growth) - Standalone EBITDA for FY25: INR 260 Mn; FY24: INR 210 Mn; EBITDA margin FY25: 32.83%, FY24: 32.86% (stable margin) - Standalone PAT for FY25: INR 199 Mn; FY24: INR 166 Mn; PAT margin FY25: 25.13%, FY24: 25.98% (slight margin decline) Overall, while absolute EBITDA and PAT rose year-on-year robustly due to higher revenues, consolidated operating and PAT margins declined.
From Remus Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY).
- Standalone Revenue from Operations for FY25 is INR 792 Mn, up from INR 639 Mn in FY24, around a 24% YoY growth.
- B2C Revenue grew from INR 11 Mn in FY24 to INR 34 Mn in FY25, with product count increasing from 5 to 14.
2 more points from Remus Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
What Remus Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Remus Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Remus Pharmaceuticals Ltd Q1 FY26 results?
For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY). EBITDA (Consolidated) for FY25: INR 457 Mn; FY24: INR 290 Mn; EBITDA margin FY25: 7.37%, FY24: 13.62% (margin decline YoY) - PAT (Consolidated) for FY25: INR 384 Mn; FY24: INR 243 Mn; PAT margin FY25: 6.19%, FY24: 11.41% (margin decline YoY) - Revenue From Operations (Consolidated) FY25: INR 6,204 Mn; FY24: INR 2,129 Mn (substantial YoY growth) - Standalone EBITDA for FY25: INR 260 Mn; FY24: INR 210 Mn; EBITDA margin FY25: 32.83%, FY24: 32.86% (stable margin) - Standalone PAT for FY25: INR 199 Mn; FY24: INR 166 Mn; PAT margin FY25: 25.13%, FY24: 25.98% (slight margin decline) Overall, while absolute EBITDA and PAT rose year-on-year robustly due to higher revenues, consolidated operating and PAT margins declined.
What is Remus Pharmaceuticals Ltd share price analysis?
Remus Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.2 with a market cap of ₹1,154 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
